Segan Louise, Kistler Peter M, Chieng David, Crowley Rose, William Jeremy, Cho Kenneth, Sugumar Hariharan, Ling Liang-Han, Voskoboinik Aleksandr, Hawson Joshua, Morton Joseph B, Lee Geoffrey, Sanders Prashanthan, Kalman Jonathan M, Prabhu Sandeep
Baker Heart and Diabetes Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia; University of Melbourne, Melbourne, Australia; Monash University, Melbourne Australia.
Baker Heart and Diabetes Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia; University of Melbourne, Melbourne, Australia; Monash University, Melbourne Australia; Melbourne Private Hospital, Melbourne, Australia.
Heart Rhythm. 2025 Jun;22(6):1429-1436. doi: 10.1016/j.hrthm.2024.09.059. Epub 2024 Sep 27.
The optimal timing of catheter ablation in individuals with atrial fibrillation (AF) and left ventricular systolic dysfunction (LVSD) remains uncertain.
We examined whether AF diagnosis to ablation time (DAT) influences outcomes following catheter ablation (CA) in patients with persistent AF (PsAF) and LVSD from the CAMERA-MRI and CAPLA randomized studies.
We evaluated clinical outcomes according to DAT < 1 year ("shorter DAT") and ≥1 year ("longer DAT"), comparing AF recurrence, AF burden, left ventricular ejection fraction (LVEF), and LV recovery (LVEF ≥ 50%) at 12 months. DAT was also compared according to the median (24 months).
Two hundred and ten individuals with AF and LVSD were identified, with a median DAT of 24 months. Shorter DAT was associated with lower LA global and posterior wall scar (<0.05 mV; both P < .05). At 12 months, 69.4% with shorter DAT (<1year) were free from recurrent atrial arrhythmias vs 53.6% in longer DAT (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.01-2.65, P = .040). Median AF burden was 0% in both groups (shorter DAT: interquartile range [IQR] 0.0-2.0% vs longer DAT: IQR 0.0-7.3%, P = .017). At 12 months, shorter DAT was associated with higher LVEF (55.3% vs 51.0%, P = .009), greater LVEF improvement (+20.8 ± 13.0% vs +13.9 ± 13.2% longer DAT, P < .001) and LV recovery (75.0% vs longer DAT: 57.2%, P = .011). Shorter DAT was associated with fewer hospitalizations and electrical cardioversions at 12 months.
In individuals with AF and LVSD, shorter DAT was associated with greater LVEF improvement and arrhythmia-free survival with lower AF burden and rehospitalization at 12 months, highlighting the prognostic benefit of early CA in AF and LVSD.
心房颤动(AF)合并左心室收缩功能障碍(LVSD)患者导管消融的最佳时机仍不确定。
我们研究了在来自CAMERA-MRI和CAPLA随机研究的持续性房颤(PsAF)和LVSD患者中,从房颤诊断到消融时间(DAT)是否会影响导管消融(CA)后的结局。
我们根据DAT<1年(“较短DAT”)和≥1年(“较长DAT”)评估临床结局,比较12个月时的房颤复发、房颤负荷、左心室射血分数(LVEF)和左心室恢复情况(LVEF≥50%)。还根据中位数(24个月)比较DAT。
确定了210例房颤合并LVSD患者,DAT中位数为24个月。较短DAT与较低的左心房整体和后壁瘢痕相关(<0.05 mV;P均<.05)。在12个月时,较短DAT组(<1年)69.4%无复发性房性心律失常,而较长DAT组为53.6%(风险比[HR]1.63,95%置信区间[CI]1.01-2.65,P=.040)。两组的房颤负荷中位数均为0%(较短DAT组:四分位间距[IQR]0.0-2.0%,较长DAT组:IQR 0.0-7.3%,P=.017)。在12个月时,较短DAT与较高的LVEF相关(55.3%对51.0%,P=.009),LVEF改善更大(较短DAT组为+20.8±13.0%,较长DAT组为+13.9±13.2%,P<.001)以及左心室恢复情况更好(75.0%对较长DAT组的有57.2%,P=.011)。较短DAT与12个月时较少的住院和电复律相关。
在房颤合并LVSD患者中,较短DAT与更大的LVEF改善以及无心律失常生存相关,12个月时房颤负荷和再住院率较低,突出了早期CA对房颤合并LVSD患者的预后益处。